Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.455 USD | +130.54% | -52.57% | -76.61% |
Mar. 27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
Mar. 27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
- Stock Market
- Equities
- MDXG Stock
- Stock
- News MiMedx Group Inc